Evidence of Brain Inflammation in Patients with Human T-Lymphotropic Virus Type 1–Associated Myelopathy (HAM): A Pilot, Multimodal Imaging Study Using 11C-PBR28 PET, MR T1-Weighted, and Diffusion-Weighted Imaging

HTLV-1–associated myelopathy (HAM; HTLV-1 is human T-lymphotropic virus type 1) is a chronic debilitating neuroinflammatory disease with a predilection for the thoracic cord. Tissue damage is attributed to the cellular immune response to HTLV-1–infected lymphocytes. The brains of HTLV-1–infected patients, with and without HAM but no clinical evidence of brain involvement, were examined using a specific 18-kDa translocator protein ligand, 11C-PBR28, and T1-weighted and diffusion-weighted MRI. Methods: Five subjects with HAM and 2 HTLV-1 asymptomatic carriers were studied. All underwent clinical neurologic assessment including cognitive function and objective measures of gait, quantification of HTLV-1 proviral load in peripheral blood mononuclear cells, and human leukocyte antigen–antigen D related expression on circulating CD8+ lymphocytes. 11C-PBR28 PET and MRI were performed on the same day. 11C-PBR28 PET total volume of distribution and distribution volume ratio (DVR) were estimated using 2-tissue-compartment modeling. MRI data were processed using tools from the FMRIB Software Library to estimate mean diffusivity (MD) and gray matter (GM) fraction changes. The results were compared with data from age-matched healthy volunteers. Results: Across the whole brain, the total volume of distribution for the subjects with HAM (5.44 ± 0.84) was significantly greater than that of asymptomatic carriers (3.44 ± 0.80). The DVR of the thalamus in patients with severe and moderate HAM was higher than that in the healthy volunteers, suggesting increased translocator protein binding (z > 4.72). Subjects with more severe myelopathy and with high DR expression on CD8+ lymphocytes had increased DVR and MD (near-significant correlation found for the right thalamus MD: P = 0.06). On the T1-weighted MRI scans, the GM fraction of the brain stem was reduced in all HTLV-1–infected patients compared with controls (P < 0.001), whereas the thalamus GM fraction was decreased in patients with HAM and correlated with the disease severity. There was no correlation between neurocognitive function and these markers of central nervous system inflammation. Conclusion: This pilot study suggests that some patients with HAM have asymptomatic inflammation in the brain, which can be detected and monitored by 11C-PBR28 PET together with structural and diffusion-weighted MRI.

[1]  M. Nowak,et al.  Genetic control and dynamics of the cellular immune response to the human T-cell leukaemia virus, HTLV-I. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[2]  Y. Itoyama,et al.  Leukoencephalopathy in HTLV-I-associated myelopathy/tropical spastic paraparesis: MRI analysis and a two year follow-up study after corticosteroid therapy , 1991, Journal of the Neurological Sciences.

[3]  E. Carvalho,et al.  Neurological Manifestations in Human T-Cell Lymphotropic Virus Type 1 (HTLV-1)-Infected Individuals Without HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis: A Longitudinal Cohort Study. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  F. Barin,et al.  ANTIBODIES TO HUMAN T-LYMPHOTROPIC VIRUS TYPE-I IN PATIENTS WITH TROPICAL SPASTIC PARAPARESIS , 1985, The Lancet.

[5]  V. Ikonomidou,et al.  Translocator Protein PET Imaging for Glial Activation in Multiple Sclerosis , 2011, Journal of Neuroimmune Pharmacology.

[6]  Y. Isashiki,et al.  Histopathological analysis of four autopsy cases of HTLV-I-associated myelopathy/tropical spastic paraparesis: inflammatory changes occur simultaneously in the entire central nervous system , 2000, Acta Neuropathologica.

[7]  Yen F. Tai,et al.  Imaging microglial activation in Huntington's disease , 2007, Brain Research Bulletin.

[8]  R. Carson,et al.  The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: A [11C]PBR28 PET study , 2013, Brain, Behavior, and Immunity.

[9]  Roger N Gunn,et al.  An 18-kDa Translocator Protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28 , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[10]  P. Mattos,et al.  Neuropsychological assessment in HTLV-1 infection: a comparative study among TSP/HAM, asymptomatic carriers, and healthy controls , 2003, Journal of neurology, neurosurgery, and psychiatry.

[11]  Robert B. Innis,et al.  Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation , 2008, NeuroImage.

[12]  J. Mugler,et al.  Rapid three‐dimensional T1‐weighted MR imaging with the MP‐RAGE sequence , 1991, Journal of magnetic resonance imaging : JMRI.

[13]  Francis J McMahon,et al.  In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. , 2013, Brain : a journal of neurology.

[14]  D. Sharp,et al.  Inflammation after trauma: Microglial activation and traumatic brain injury , 2011, Annals of neurology.

[15]  E. Majorovits,et al.  The immune control of HTLV-1 infection: selection forces and dynamics. , 2009, Frontiers in bioscience.

[16]  Timothy Edward John Behrens,et al.  Characterization and propagation of uncertainty in diffusion‐weighted MR imaging , 2003, Magnetic resonance in medicine.

[17]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[18]  S. Gunn,et al.  Positron Emission Tomography Compartmental Models , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[19]  Roger N Gunn,et al.  Quantification of the Specific Translocator Protein Signal of 18F-PBR111 in Healthy Humans: A Genetic Polymorphism Effect on In Vivo Binding , 2013, The Journal of Nuclear Medicine.

[20]  Mark Jenkinson,et al.  Imaging dopamine receptors in humans with [11C]-(+)-PHNO: Dissection of D3 signal and anatomy , 2011, NeuroImage.

[21]  M. Saito Neuroimmunological aspects of human T cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis , 2014, Journal of NeuroVirology.

[22]  W. Blattner,et al.  Incidence of HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica and Trinidad. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[23]  S. Yamamoto,et al.  An autopsy case of human T-lymphotropic virus type I-associated myelopathy. , 1988, Human pathology.

[24]  S. Zoghbi,et al.  Stroke incidentally identified using improved positron emission tomography for microglial activation. , 2009, Archives of neurology.

[25]  J. Oger,et al.  Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). , 2006, AIDS research and human retroviruses.

[26]  S. Wain-Hobson,et al.  Common human T cell leukemia virus type 1 (HTLV-1) integration sites in cerebrospinal fluid and blood lymphocytes of patients with HTLV-1-associated myelopathy/tropical spastic paraparesis indicate that HTLV-1 crosses the blood-brain barrier via clonal HTLV-1-infected cells. , 2000, The Journal of infectious diseases.

[27]  S. Izumo,et al.  Neuropathology of HTLV‐I‐Associated Myelopathy—A Report of Two Autopsy Cases— , 1992, Acta paediatrica Japonica : Overseas edition.

[28]  S. Izumo,et al.  Activation of macrophages/microglia with the calcium-binding proteins MRP14 and MRP8 is related to the lesional activities in the spinal cord of HTLV-I associated myelopathy , 1999, Journal of Neurology.

[29]  Hervé Boutin,et al.  Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[31]  D. Smith,et al.  Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study , 2003, Neurology.

[32]  A. Gessain,et al.  Epidemiological Aspects and World Distribution of HTLV-1 Infection , 2012, Front. Microbio..

[33]  M. Nakagawa,et al.  Immunocytochemical Analysis of the Cellular Infiltrate in the Spinal Cord Lesions in HTLV‐I‐Associated Myelopathy , 1993, Journal of neuropathology and experimental neurology.

[34]  Timothy Edward John Behrens,et al.  Anatomically related grey and white matter abnormalities in adolescent-onset schizophrenia. , 2007, Brain : a journal of neurology.

[35]  J. Weber,et al.  Preferential Infection with HTLV-I Immunodominance Hierarchy and T Cells : + ( HTLV-I )-Specific CD 4 Human T Cell Lymphotropic Virus Type I , 2004 .